169 related articles for article (PubMed ID: 38102204)
21. Genetic deletions in AML and MDS.
Ebert BL
Best Pract Res Clin Haematol; 2010 Dec; 23(4):457-61. PubMed ID: 21130407
[TBL] [Abstract][Full Text] [Related]
22. Sustained OMA1-mediated integrated stress response is beneficial for spastic ataxia type 5.
Franchino CA; Brughera M; Baderna V; De Ritis D; Rocco A; Seneca S; Regal L; Podini P; D'Antonio M; Toro C; Quattrini A; Scalais E; Maltecca F
Brain; 2024 Mar; 147(3):1043-1056. PubMed ID: 37804316
[TBL] [Abstract][Full Text] [Related]
23. New complex t(2;11;17)(p21;q23;q11), a variant form of t(2;11), associated with del(5)(q23q32) in myelodysplastic syndrome-derived acute myeloblastic leukemia.
Yamamoto K; Nagata K; Morita Y; Inagaki K; Hamaguchi H
Cancer Genet Cytogenet; 2002 Sep; 137(2):119-23. PubMed ID: 12393282
[TBL] [Abstract][Full Text] [Related]
24. Is monosomy 5 an uncommon aberration? Fluorescence in situ hybridization reveals translocations and deletions in myelodysplastic syndromes or acute myelocytic leukemia.
Bram S; Swolin B; Rödjer S; Stockelberg D; Ogärd I; Bäck H
Cancer Genet Cytogenet; 2003 Apr; 142(2):107-14. PubMed ID: 12699885
[TBL] [Abstract][Full Text] [Related]
25. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Adema V; Palomo L; Walter W; Mallo M; Hutter S; La Framboise T; Arenillas L; Meggendorfer M; Radivoyevitch T; Xicoy B; Pellagatti A; Haferlach C; Boultwood J; Kern W; Visconte V; Sekeres M; Barnard J; Haferlach T; Solé F; Maciejewski JP
EBioMedicine; 2022 Jun; 80():104059. PubMed ID: 35617825
[TBL] [Abstract][Full Text] [Related]
26. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of
Abbas HA; Ayoub E; Sun H; Kanagal-Shamanna R; Short NJ; Issa G; Yilmaz M; Pierce S; Rivera D; Cham B; Wing S; Li Z; Hammond D; Jabbour E; Borthakur G; Garcia-Manero G; Andreeff M; Daver N; Kadia T; Konopleva M; DiNardo C; Ravandi F
Leuk Lymphoma; 2022 Dec; 63(13):3105-3116. PubMed ID: 36089905
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients.
Douet-Guilbert N; De Braekeleer E; Basinko A; Herry A; Gueganic N; Bovo C; Trillet K; Dos Santos A; Le Bris MJ; Morel F; Eveillard JR; Berthou C; De Braekeleer M
Leukemia; 2012 Jul; 26(7):1695-7. PubMed ID: 22290067
[No Abstract] [Full Text] [Related]
29. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
Wei S; Chen X; Rocha K; Epling-Burnette PK; Djeu JY; Liu Q; Byrd J; Sokol L; Lawrence N; Pireddu R; Dewald G; Williams A; Maciejewski J; List A
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12974-9. PubMed ID: 19470455
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Gaballa MR; Besa EC
Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.
Qian Z; Joslin JM; Tennant TR; Reshmi SC; Young DJ; Stoddart A; Larson RA; Le Beau MM
Chem Biol Interact; 2010 Mar; 184(1-2):50-7. PubMed ID: 19958752
[TBL] [Abstract][Full Text] [Related]
32. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
33. Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc.
Stoddart A; Wang J; Fernald AA; Karrison T; Anastasi J; Le Beau MM
Blood; 2014 Jan; 123(2):228-38. PubMed ID: 24264229
[TBL] [Abstract][Full Text] [Related]
34. Coexistent t(8;21)(q22;q22) Translocation and 5q Deletion in Acute Myeloid Leukemia.
Yamamoto K; Yakushijin K; Sanada Y; Kawamoto S; Matsuoka H; Minami H
J Clin Exp Hematop; 2015; 55(3):181-5. PubMed ID: 26763368
[TBL] [Abstract][Full Text] [Related]
35. NPM1 deletion is associated with gross chromosomal rearrangements in leukemia.
La Starza R; Matteucci C; Gorello P; Brandimarte L; Pierini V; Crescenzi B; Nofrini V; Rosati R; Gottardi E; Saglio G; Santucci A; Berchicci L; Arcioni F; Falini B; Martelli MF; Sambani C; Aventin A; Mecucci C
PLoS One; 2010 Sep; 5(9):e12855. PubMed ID: 20877721
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.
Liu T; Krysiak K; Shirai CL; Kim S; Shao J; Ndonwi M; Walter MJ
PLoS One; 2017; 12(2):e0170470. PubMed ID: 28178280
[TBL] [Abstract][Full Text] [Related]
37. 5q-: pathogenetic importance of the common deleted region and clinical consequences of the entire deleted segment.
Pedersen B
Anticancer Res; 1993; 13(5C):1913-6. PubMed ID: 8267400
[TBL] [Abstract][Full Text] [Related]
38. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML.
Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; De Braekeleer M
Eur J Haematol; 2007 Jun; 78(6):457-67. PubMed ID: 17391336
[TBL] [Abstract][Full Text] [Related]
39. Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31).
Green WB; Slovak ML; Chen IM; Pallavicini M; Hecht JL; Willman CL
Leukemia; 1999 Dec; 13(12):1960-71. PubMed ID: 10602416
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
Sekeres MA; Gundacker H; Lancet J; Advani A; Petersdorf S; Liesveld J; Mulford D; Norwood T; Willman CL; Appelbaum FR; List AF
Blood; 2011 Jul; 118(3):523-8. PubMed ID: 21551228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
